21, 2025, the FDA announced that the semaglutide shortage was over and that compounding pharmacies need to stop making and selling semaglutide injection products that are copies of FDA-approved products (Ozempic, Wegovy, and Rybelsus)
Comparing intranasal retatrutide to other nasal peptides Intranasal retatrutide is not the first peptide to be explored through nasal delivery
Clinical trials show modest improvements in cholesterol profiles with Saxenda, primarily through weight loss
Once-weekly GLP-1 medications like semaglutide (Ozempic) and dulaglutide (Trulicity) offer greater convenience with less frequent injections, while once-daily options like liraglutide (Victoza) may provide more consistent day-to-day effects
Many peptides are FDA-approved and often require a prescription to ensure safety, efficacy, and pharmaceutical-grade quality